Frequency of the primary endpoint and its individual components in relation to quartiles of hsCRP
| HR (95% CI)* | χ2 | p Value | |
| Clopidogrel vs placebo in hsCRP <3 mg/l | 0.69 (0.52 to 0.93) | 6.13 | 0.013 |
| Clopidogrel vs placebo in hsCRP ≥3 mg/l | 0.94 (0.75 to 1.18) | 0.28 | 0.60 |
| Multiple risk factors vs CVD | 0.56 (0.43 to 0.72) | 19.7 | <0.001 |
| Age, years | 1.05 (1.04 to 1.06) | 84.61 | <0.001 |
| Male | 1.43 (1.17 to 1.76) | 11.62 | 0.001 |
| BMI, kg/m2 | 0.98 (0.96 to 0.997) | 5.30 | 0.02 |
| Diabetes | 1.76 (1.45 to 2.14) | 32.82 | <0.001 |
| Hypertension | 1.04 (0.83 to 1.30) | 0.09 | 0.76 |
| Hypercholesterolaemia | 1.02 (0.81 to 1.29) | 0.03 | 0.87 |
| Current smoker | 1.31 (1.05 to 1.64) | 5.48 | 0.019 |
| Previous statins | 0.79 (0.64 to 0.98) | 4.52 | 0.034 |
| Previous angiotensin II antagonists | 1.01 (0.79 to 1.29) | 0.003 | 0.95 |
| Previous ramipril | 0.86 (0.64 to 1.17) | 0.94 | 0.33 |
| Aspirin daily dose, mg | 1.003 (1.00 to 1.01) | 3.79 | 0.05 |
↵* Adjusted for treatment, gender, age, body mass index (BMI), diabetes mellitus, hypertension, hypercholesterolaemia, current smoker, previous statins, angiotensin antagonist or ACE inhibitor medication, aspirin dose and evident cardiovascular disease (CVD) versus multiple cardiovascular risk factors.
hsCRP, high-sensitivity C-reactive protein.